\

Основна інформація

• Доступно на:
• English
• Український

Introducing the EarlyTect Colon Cancer Test, an innovative screening tool specifically designed for the early detection of colorectal cancer. This groundbreaking product has received approval from the Korea Ministry of Food and Drug Safety after undergoing rigorous clinical trials at renowned medical centers such as the Yonsei Medical Center, Severance Hospital, and Severance Check-up Center.

Utilizing fecal DNA samples, the EarlyTect Colon Cancer Test has demonstrated impressive accuracy in diagnosing colorectal cancer. With a sensitivity and specificity rate of 90%, this qualitative real-time PCR test measures the presence of methylated Syndecan-2, a clinically significant biomarker associated with precancerous lesions of colorectal cancer.

It is important to note that the purpose of the EarlyTect Colon Cancer Test is not to confirm the presence of colorectal cancer itself, but rather to identify potential cases that may require further investigation. If a subject tests positive, it suggests the existence of either colorectal cancer or precancerous lesions associated with it.

The product adheres to the following standards:

- Cancer Type: Colorectal Cancer
- Subject: Asymptomatic individuals undergoing colorectal cancer screening
- Biomarker: SDC2 methylation

For pricing and transaction details, please contact us to request a quote. We are open to negotiations and eager to facilitate the availability of this vital screening tool.